These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32614795)

  • 1. Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia.
    Tekalign S; Adera C; Den Boer M; Miecha H; Zewde A; Mulugeta D; Bishawu T; Birru W; Lema A; Sahlu T; Alves F; Manzi M; Takarinda K; Van Griensven J
    J Infect Dev Ctries; 2020 Jun; 14(6.1):42S-47S. PubMed ID: 32614795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia.
    Diro E; Lynen L; Gebregziabiher B; Assefa A; Lakew W; Belew Z; Hailu A; Boelaert M; van Griensven J
    Trop Med Int Health; 2015 Jan; 20(1):8-16. PubMed ID: 25329449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
    Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?
    Aderie EM; Diro E; Zachariah R; da Fonseca MS; Abongomera C; Dolamo BL; Ritmeijer K
    Trans R Soc Trop Med Hyg; 2017 Mar; 111(3):107-116. PubMed ID: 28633331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R; Musa AM; Njoroge S; Omollo R; Alves F; Hailu A; Khalil EA; Diro E; Soipei P; Musa B; Salman K; Ritmeijer K; Chappuis F; Rashid J; Mohammed R; Jameneh A; Makonnen E; Olobo J; Okello L; Sagaki P; Strub N; Ellis S; Alvar J; Balasegaram M; Alirol E; Wasunna M
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
    Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
    Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
    Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral leishmaniasis and leishmaniasis-HIV coinfection: comparative study.
    Coutinho JVSC; Santos FSD; Ribeiro RDSP; Oliveira IBB; Dantas VB; Santos ABFS; Tauhata JR
    Rev Soc Bras Med Trop; 2017; 50(5):670-674. PubMed ID: 29160515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
    Medrano FJ; Hernández-Quero J; Jiménez E; Pineda JA; Rivero A; Sánchez-Quijano A; Velez ID; Viciana P; Castillo R; Reyes MJ
    AIDS; 1992 Dec; 6(12):1499-503. PubMed ID: 1362880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
    Hurissa Z; Gebre-Silassie S; Hailu W; Tefera T; Lalloo DG; Cuevas LE; Hailu A
    Trop Med Int Health; 2010 Jul; 15(7):848-55. PubMed ID: 20487426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; van Loen H; Tsoumanis A; Adriaensen W; Hailu A; Griensven JV
    Clin Infect Dis; 2018 Jan; 66(3):444-451. PubMed ID: 29020217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
    Mengstie TA; Endale HT; Mulaw T; Abdella AM; Mohammed R; Malik T; Dessie G
    PLoS One; 2021; 16(10):e0257229. PubMed ID: 34597312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
    Goyal V; Burza S; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Das VNR; Bern C; Hightower A; Rijal S; Sunyoto T; Alves F; Lima N; Das P; Alvar J
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007726. PubMed ID: 31557162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
    Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.